Paul M. Grandgenett

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S1 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S10 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S2 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S6 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S8 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S3 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S7 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S4 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S5 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S9 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Supplementary Figure S11 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

  2026-06-17

• Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer

  Cell Reports · 2026-06-01

• Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity

  Cancer Cell · 2026-04-30 · 2 citations

• The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion

  Developmental Cell · 2026-04-30 · 2 citations

• Abstract 7358: MYB expression increases progressively in pancreatic cancer, correlating with advancing tumor grade, metastasis, and poor patient survival

  Cancer Research · 2026-04-03

• Differences in collagen structure and organization in primary and metastatic pancreatic cancer and the effects of FOLFIRINOX treatment

  Matrix Biology Plus · 2026-03-17

• A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression

  Cancer Letters · 2026-03-07

• Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer

  Cancers · 2025-11-01

• Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway

  Biomedicine & Pharmacotherapy · 2025-10-28

• Abstract A005: An Iron-regulated Signalling Pathway Controls Adipose Browning and Cancer Cachexia

  Cancer Research · 2025-09-28